FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2733992941> ?p ?o ?g. }

• W2733992941 endingPage "e0005576" @default.
• W2733992941 startingPage "e0005576" @default.
• W2733992941 abstract "Background Individuals with high intensity of Loa loa are at risk of developing serious adverse events (SAEs) post treatment with ivermectin. These SAEs have remained unclear and a programmatic impediment to the advancement of community directed treatment with ivermectin. The pathogenesis of these SAEs following ivermectin has never been investigated experimentally. The Loa/baboon (Papio anubis) model can be used to investigate the pathogenesis of Loa-associated encephalopathy following ivermectin treatment in humans. Methods 12 baboons with microfilarial loads > 8,000mf/mL of blood were randomised into four groups: Group 1 (control group receiving no drug), Group 2 receiving ivermectin (IVM) alone, Group 3 receiving ivermectin plus aspirin (IVM + ASA), and Group 4 receiving ivermectin plus prednisone (IVM + PSE). Blood samples collected before treatment and at Day 5, 7 or 10 post treatment, were analysed for parasitological, hematological and biochemical parameters using standard techniques. Clinical monitoring of animals for side effects took place every 6 hours post treatment until autopsy. At autopsy free fluids and a large number of standard organs were collected, examined and tissues fixed in 10% buffered formalin and processed for standard haematoxylin-eosin staining and specific immunocytochemical staining. Results Mf counts dropped significantly (p<0.05) in all animals following ivermectin treatment with reductions as high as (89.9%) recorded; while no significant drop was observed in the control animals. Apart from haemoglobin (Hb) levels which recorded a significant (p = 0.028) drop post treatment, all other haematological and biochemical parameters did not show any significant changes (p>0.05). All animals became withdrawn 48 hours after IVM administration. All treated animals recorded clinical manifestations including rashes, itching, diarrhoea, conjunctival haemorrhages, lymph node enlargement, pinkish ears, swollen face and restlessness; one animal died 5 hours after IVM administration. Macroscopic changes in post-mortem tissues observed comprised haemorrhages in the brain, lungs, heart, which seen in all groups given ivermectin but not in the untreated animals. Microscopically, the major cellular changes seen, which were present in all the ivermectin treated animals included microfilariae in varying degrees of degeneration in small vessels. These were frequently associated with fibrin deposition, endothelial changes including damage to the integrity of the blood vessel and the presence of extravascular erythrocytes (haemorrhages). There was an increased presence of eosinophils and other chronic inflammatory types in certain tissues and organs, often in large numbers and associated with microfilarial destruction. Highly vascularized organs like the brain, heart, lungs and kidneys were observed to have more microfilariae in tissue sections. The number of mf seen in the brain and kidneys of animals administered IVM alone tripled that of control animals. Co-administration of IVM + PSE caused a greater increase in mf in the brain and kidneys while the reverse was noticed with the co-administration of IVM + ASA. Conclusions The treatment of Loa hyper-microfilaraemic individuals with ivermectin produces a clinical spectrum that parallels that seen in Loa hyper-microfilaraemic humans treated with ivermectin. The utilization of this experimental model can contribute to the improved management of the adverse responses in humans." @default.
• W2733992941 created "2017-07-14" @default.
• W2733992941 creator A5001221796 @default.
• W2733992941 creator A5013334382 @default.
• W2733992941 creator A5015289984 @default.
• W2733992941 creator A5029917850 @default.
• W2733992941 creator A5035731664 @default.
• W2733992941 creator A5042538588 @default.
• W2733992941 creator A5048131023 @default.
• W2733992941 creator A5070939184 @default.
• W2733992941 creator A5071336899 @default.
• W2733992941 creator A5079454688 @default.
• W2733992941 creator A5082739299 @default.
• W2733992941 creator A5082864111 @default.
• W2733992941 date "2017-07-07" @default.
• W2733992941 modified "2023-09-27" @default.
• W2733992941 title "Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment" @default.
• W2733992941 cites W144183601 @default.
• W2733992941 cites W1577384787 @default.
• W2733992941 cites W1792453644 @default.
• W2733992941 cites W1793547999 @default.
• W2733992941 cites W1918160013 @default.
• W2733992941 cites W1978095335 @default.
• W2733992941 cites W2003961532 @default.
• W2733992941 cites W2048972202 @default.
• W2733992941 cites W2064175542 @default.
• W2733992941 cites W2112154467 @default.
• W2733992941 cites W2117040738 @default.
• W2733992941 cites W2120093614 @default.
• W2733992941 cites W2130300200 @default.
• W2733992941 cites W2135996962 @default.
• W2733992941 cites W2153086068 @default.
• W2733992941 cites W2153827704 @default.
• W2733992941 cites W2153942663 @default.
• W2733992941 cites W2154219368 @default.
• W2733992941 cites W2154835816 @default.
• W2733992941 cites W2167216497 @default.
• W2733992941 cites W2168048436 @default.
• W2733992941 cites W2169215342 @default.
• W2733992941 cites W2170682979 @default.
• W2733992941 cites W2337515024 @default.
• W2733992941 cites W2346500045 @default.
• W2733992941 cites W2359251140 @default.
• W2733992941 cites W2399252093 @default.
• W2733992941 cites W2399754173 @default.
• W2733992941 cites W2404174958 @default.
• W2733992941 cites W2424447660 @default.
• W2733992941 cites W256894870 @default.
• W2733992941 cites W4237345625 @default.
• W2733992941 cites W62604938 @default.
• W2733992941 doi "https://doi.org/10.1371/journal.pntd.0005576" @default.
• W2733992941 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5533442" @default.
• W2733992941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28686693" @default.
• W2733992941 hasPublicationYear "2017" @default.
• W2733992941 type Work @default.
• W2733992941 sameAs 2733992941 @default.
• W2733992941 citedByCount "29" @default.
• W2733992941 countsByYear W27339929412018 @default.
• W2733992941 countsByYear W27339929412019 @default.
• W2733992941 countsByYear W27339929412020 @default.
• W2733992941 countsByYear W27339929412021 @default.
• W2733992941 countsByYear W27339929412022 @default.
• W2733992941 countsByYear W27339929412023 @default.
• W2733992941 crossrefType "journal-article" @default.
• W2733992941 hasAuthorship W2733992941A5001221796 @default.
• W2733992941 hasAuthorship W2733992941A5013334382 @default.
• W2733992941 hasAuthorship W2733992941A5015289984 @default.
• W2733992941 hasAuthorship W2733992941A5029917850 @default.
• W2733992941 hasAuthorship W2733992941A5035731664 @default.
• W2733992941 hasAuthorship W2733992941A5042538588 @default.
• W2733992941 hasAuthorship W2733992941A5048131023 @default.
• W2733992941 hasAuthorship W2733992941A5070939184 @default.
• W2733992941 hasAuthorship W2733992941A5071336899 @default.
• W2733992941 hasAuthorship W2733992941A5079454688 @default.
• W2733992941 hasAuthorship W2733992941A5082739299 @default.
• W2733992941 hasAuthorship W2733992941A5082864111 @default.
• W2733992941 hasBestOaLocation W27339929411 @default.
• W2733992941 hasConcept C126322002 @default.
• W2733992941 hasConcept C165901193 @default.
• W2733992941 hasConcept C197934379 @default.
• W2733992941 hasConcept C203014093 @default.
• W2733992941 hasConcept C2776031002 @default.
• W2733992941 hasConcept C2777499811 @default.
• W2733992941 hasConcept C2777629521 @default.
• W2733992941 hasConcept C42407357 @default.
• W2733992941 hasConcept C42972112 @default.
• W2733992941 hasConcept C71924100 @default.
• W2733992941 hasConcept C90924648 @default.
• W2733992941 hasConceptScore W2733992941C126322002 @default.
• W2733992941 hasConceptScore W2733992941C165901193 @default.
• W2733992941 hasConceptScore W2733992941C197934379 @default.
• W2733992941 hasConceptScore W2733992941C203014093 @default.
• W2733992941 hasConceptScore W2733992941C2776031002 @default.
• W2733992941 hasConceptScore W2733992941C2777499811 @default.
• W2733992941 hasConceptScore W2733992941C2777629521 @default.
• W2733992941 hasConceptScore W2733992941C42407357 @default.
• W2733992941 hasConceptScore W2733992941C42972112 @default.
• W2733992941 hasConceptScore W2733992941C71924100 @default.

• next